p-Cymen-7-ol, also widely called cuminol or cumin alcohol, is a cumin-associated aromatic alcohol that appears in smaller amounts across spice and herb essential-oil literature. The strongest live evidence for this constituent is identity, synonym control, odor character, natural occurrence, and fragrance-safety restriction data rather than robust stand-alone pharmacology. A few constituent-specific papers exist, but the evidence base is still thin enough that AromaForge should describe p-cymen-7-ol mainly as a spice-note marker with limited isolated-research depth.
Chemical identity and composition
PubChem resolves p-cymen-7-ol to CID 325 under the preferred title Cuminol, with formula C10H14O and IUPAC name (4-propan-2-ylphenyl)methanol. PubChem synonym data links the archive spelling p-cymen-7-ol to cuminol, cuminyl alcohol, and p-isopropylbenzyl alcohol. IFRA's ingredient standard uses the same synonym cluster and treats it as a restricted fragrance ingredient.
Aroma and practical use
- Use the recorded spicy, cumin, caraway, herbal, leathery, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2013 paper on cumin seed components reported that cuminaldehyde and cuminol acted as insulinotropic components in cell and islet experiments, providing one of the few isolated constituent-specific activity signals for p-cymen-7-ol.
A 2013 paper on cumin seed components reported that cuminaldehyde and cuminol acted as insulinotropic components in cell and islet experiments, providing one of the few isolated constituent-specific activity signals for p-cymen-7-ol.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
A 2021 spectroscopic binding study described weak binding between cuminol and bovine serum albumin, reinforcing that the accessible literature is still mainly physicochemical and preclinical.
A 2021 spectroscopic binding study described weak binding between cuminol and bovine serum albumin, reinforcing that the accessible literature is still mainly physicochemical and preclinical.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedIFRA Standard 194 restricts p-isopropylbenzyl alcohol and explicitly states that dermal sensitization and systemic toxicity were the intrinsic properties driving risk management.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
An IFF SDS excerpt surfaced by public search classifies cuminyl alcohol as Acute Toxicity Category 4 (H302), and the same document notes a non-irritating 48-hour closed human patch result alongside rabbit skin irritation data.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No strong human clinical literature was located for isolated p-cymen-7-ol, and most public mentions appear in compositional tables rather than targeted pharmacology studies.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
insulinotropic signal in cell and islet models
One constituent-specific paper identified cuminol as one of the insulinotropic components in cumin seed extract work, but this remains an early preclinical signal rather than an archive-level benefit claim.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
protein binding interaction
Spectroscopy studies report weak binding between cuminol and serum albumin model proteins, which is useful as mechanistic chemistry context but not as a consumer-facing effect claim.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- The isolated p-cymen-7-ol literature is sparse relative to better studied terpenes and alcohols.
- Most public mentions are occurrence tables or safety listings rather than direct functional studies.
- No robust human clinical efficacy or tolerability studies for isolated p-cymen-7-ol were located in this pass.
- This pass confirmed IFRA Standard 194 (p-isopropylbenzyl alcohol) is an active restriction driven by dermal sensitization and systemic toxicity, but could not re-extract the exact per-category maximum percentage from the primary PDF in this pass; the existing 0.1% figure is retained from prior full-text review of IFRA Standard 194 (Amendment 49) noted in sources.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Some findings lack a directly linked source; treat those entries as unverified research notes.